Acrivon Therapeutics, Inc.
ACRVNasdaq
$1.75
0.0%Jul 17 close · end-of-day
Price
1Y↑ +34.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$67.8M
Enterprise Value
-$30.0M
P/E
—
P/S
—
P/B
0.7
EV/EBITDA
—
PEG
—
FCF Yield
-97.8%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$77.3M
Free Cash Flow (TTM)
-$66.3M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-80.9%
ROIC
—
Debt / Equity
—
Net Cash
$97.7M
Return 1Y
+32.6%
Company profile
We are a clinical stage biopharmaceutical company developing precision oncology medicines that we match to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing our proprietary proteomics-based patient responder identification platform. We were incorporated under the laws of the State of Delaware in March 2018. Our principal executive offices are located at 480 Arsenal Way, Suite 100, Watertown, Massachusetts.
- CEO
- Peter Blume-Jensen
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- Massachusetts
- Website
- acrivon.com
Management & directors
- Blume-Jensen PeterPresident and CEO
- Devroe EricChief Operating Officer
- Gamelin ErickChief Development Officer
- Levy Adam D.Chief Financial Officer
- Miller MaryChief Legal Officer
- Mirza Mansoor RazaChief Medical Officer
- Peterson KatharineChief Accounting Officer
Roles derived from SEC Form 4 filings.
Earnings
ACRV Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.49↓ -3.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$16.2M | -$32.7M | -$67.1M | -$89.2M | -$84.1M |
| Net income | -$16.2M | -$31.2M | -$60.4M | -$80.6M | -$77.9M |
| Diluted EPS | -$9.32 | -$7.56 | -$2.74 | -$2.38 | -$2.02 |
| Operating cash flow | -$14.0M | -$30.1M | -$42.6M | -$65.7M | -$63.7M |
| Free cash flow | -$14.2M | -$32.3M | -$43.9M | -$68.4M | -$65.3M |
| Gross margin | — | — | — | — | — |
| Operating margin | — | — | — | — | — |
| Net margin | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$21.4M | -$25.1M | -$25.0M | -$21.7M | -$22.6M | -$19.7M | -$20.1M | -$19.9M |
| Net income | -$18.8M | -$22.4M | -$22.8M | -$19.7M | -$21.0M | -$18.2M | -$19.0M | -$19.0M |
| Diluted EPS | -$0.52 | -$0.59 | -$0.54 | -$0.51 | -$0.55 | -$0.47 | -$0.49 | -$0.49 |
| Operating cash flow | -$13.9M | -$17.3M | -$17.4M | -$19.5M | -$16.6M | -$12.3M | -$15.2M | -$20.5M |
| Free cash flow | -$14.0M | -$18.3M | -$18.2M | -$19.6M | -$17.1M | -$13.2M | -$15.5M | -$20.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
May 21, 2026
May 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-21 | Blume-Jensen Peter· President and CEO | Tax withholding | 13,729 | $1.79 | $24,574.91 | filing |
| 2026-05-18 | RA CAPITAL MANAGEMENT, LLC | Award | 9,366 | $0.00 | $0.00 | filing |
| 2026-05-18 | TOMSICEK MICHAEL JOHN | Award | 9,366 | $0.00 | $0.00 | filing |
| 2026-05-18 | Shacham Sharon | Award | 9,366 | $0.00 | $0.00 | filing |
| 2026-05-18 | Palani Santhosh | Award | 9,366 | $0.00 | $0.00 | filing |
| 2026-05-18 | Magovcevic Ivana | Award | 9,366 | $0.00 | $0.00 | filing |
| 2026-05-18 | DiRocco Derek | Award | 9,366 | $0.00 | $0.00 | filing |
| 2026-05-18 | BAUM CHARLES M | Award | 9,366 | $0.00 | $0.00 | filing |
| 2026-05-18 | Peterson Katharine· Chief Accounting Officer | Award | 14,227 | $0.00 | $0.00 | filing |
| 2026-05-18 | Mirza Mansoor Raza· Chief Medical Officer | Award | 38,817 | $0.00 | $0.00 | filing |
| 2026-05-18 | Miller Mary· Chief Legal Officer | Award | 49,830 | $0.00 | $0.00 | filing |
| 2026-05-18 | Levy Adam D.· Chief Financial Officer | Award | 46,167 | $0.00 | $0.00 | filing |
| 2026-05-18 | Gamelin Erick· Chief Development Officer | Award | 38,584 | $0.00 | $0.00 | filing |
| 2026-05-18 | Devroe Eric· Chief Operating Officer | Award | 72,981 | $0.00 | $0.00 | filing |
| 2026-05-18 | Blume-Jensen Peter· President and CEO | Award | 180,095 | $0.00 | $0.00 | filing |
| 2026-05-18 | Blume-Jensen Peter· President and CEO | Award | 72,706 | $0.00 | $0.00 | filing |
| 2026-05-14 | Blume-Jensen Peter· President and CEO | Tax withholding | 1,253 | $1.92 | $2,405.76 | filing |
| 2026-05-14 | Devroe Eric· Chief Operating Officer | Tax withholding | 613 | $1.92 | $1,176.96 | filing |
| 2026-05-14 | Blume-Jensen Peter· President and CEO | Tax withholding | 490 | $1.92 | $940.80 | filing |
| 2026-05-14 | Gamelin Erick· Chief Development Officer | Tax withholding | 404 | $1.92 | $775.68 | filing |
| 2026-05-14 | Miller Mary· Chief Legal Officer | Tax withholding | 184 | $1.92 | $353.28 | filing |
| 2026-05-14 | Peterson Katharine· Chief Accounting Officer | Tax withholding | 99 | $1.92 | $190.08 | filing |
| 2026-04-22 | RA CAPITAL MANAGEMENT, LLC | Award | 3,888,888 | $1.80 | $7.0M | filing |
| 2026-04-17 | Miller Mary· Chief Legal Officer | Tax withholding | 558 | $1.78 | $993.24 | filing |
| 2026-02-21 | Blume-Jensen Peter· President and CEO | Tax withholding | 14,265 | $1.53 | $21,825.45 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.